HSBC/CALL/MODERNA/220/0.1/15.01.25 | Real-time Boerse Frankfurt Warrants 08:05:48 25/06/2024 BST | ||
| 0.47 EUR | -2.08% |
|
| Current month | -29.41% | ||
| 1 month | -67.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 0.47 | -2.08% |
| 24/06/24 | 0.48 | +4.35% |
| 21/06/24 | 0.46 | -4.17% |
| 20/06/24 | 0.48 | +14.29% |
| 19/06/24 | 0.42 | -10.64% |
Real-time Boerse Frankfurt Warrants
Last update June 25, 2024 at 08:05 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807J |
| ISIN | DE000HG807J5 |
| Date issued | 02/02/2023 |
| Strike | 220 $ |
| Maturity | 15/01/2025 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 4.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.1 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.03 € |
| Spread % | 6.00% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137
USD
Average target price
145.9
USD
Spread / Average Target
+6.46%
- Stock Market
- Warrants
- Warrant
